Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Management tracks

    Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head …

    Published on 1/13/2017
  • COMPANY NEWS: Tesaro gets CRL for IV rolapitant

    Tesaro Inc. (NASDAQ:TSRO) received a complete response letter from FDA for biotech's IV formulation of rolapitant (SCH 619734) to prevent chemotherapy-induced nausea and vomiting (CINV).At FDA's request during the NDA …

    Published on 1/12/2017
  • COMPANY NEWS: FDA reviewing Herceptin biosimilar from Mylan, Biocon

    Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said FDA accepted for review a BLA for Myl-1401O, their proposed biosimilar of Herceptin trastuzumab to treat HER2-positive breast cancer. The BsUFA date …

    Published on 1/11/2017
  • COMPANY NEWS: NICE recommends Afinitor for second-line RCC

    In draft guidance issued Wednesday, the U.K.'s NICE recommended that Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN) be routinely available on the NHS to treat advanced renal cell carcinoma that progressed …

    Published on 1/11/2017
  • COMPANY NEWS: Priority Review for Keytruda in broad NSCLC indication

    Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab in a broader first-line non-small cell lung cancer indication than that for which the drug is already …

    Published on 1/11/2017
  • COMPANY NEWS: Vertex grants Merck KGaA rights to cancer programs

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to four cancer programs. Vertex is to receive $230 million up front and is eligible for royalties. Merck will be …

    Published on 1/11/2017
  • COMPANY NEWS: Illumina rises after introducing new products, deals

    Illumina Inc. (NASDAQ:ILMN) gained $23.50 (17%) to $165.04 on Tuesday after introducing new products and collaborations, including the launch of the NovaSeq series of high throughput sequencers. The company said the …

    Published on 1/10/2017
  • COMPANY NEWS: Kite, Fosun create China-based JV

    Kite Pharma Inc. (NASDAQ:KITE) and Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) formed a joint venture to develop Kite's lead chimeric antigen receptor (CAR) T cell immunotherapy candidate, …

    Published on 1/10/2017
  • COMPANY NEWS: Valeant selling Dendreon to Chinese conglomerate

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) is selling cancer company Dendreon Pharmaceuticals Inc. to Sanpower Group Co. Ltd. (Nanjing, China) for $819.9 million in cash. Valeant expects the deal to …

    Published on 1/10/2017
  • COMPANY NEWS: Allergan in deals with Lysosomal Therapeutics, Assembly

    Allergan plc (NYSE:AGN) announced two deals Monday, gaining an exclusive option to acquire neurodegenerative disease company Lysosomal Therapeutics Inc. (Cambridge, Mass.) and a license for rights to four …

    Published on 1/9/2017
  • COMPANY NEWS: Amgen, Immatics in bispecifics deal

    Amgen Inc. (NASDAQ:AMGN) and Immatics Biotechnologies GmbH (Tuebingen, Germany) partnered to develop T cell engaging bispecific immunotherapies to treat cancer. Immatics is to receive $30 million up front and is …

    Published on 1/9/2017
  • COMPANY NEWS: Celgene partners with Anokion, lifts 2017 guidance

    Celgene Corp. (NASDAQ:CELG) and Anokion S.A. (Ecublens, Switzerland) partnered to use the Swiss biotech's immune tolerizing platform to develop therapies for autoimmune diseases. Celgene made an equity investment in …

    Published on 1/9/2017
  • COMPANY NEWS: Daiichi gets Japan rights to Kite's CAR T

    Kite Pharma Inc. (NASDAQ:KITE) said it granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) rights in Japan to develop and commercialize chimeric antigen receptor T cell therapy axicabtagene ciloleucel (KTE-C19).Kite is to …

    Published on 1/9/2017
  • COMPANY NEWS: FDA approves Egalet's Arymo

    FDA approved Arymo ER morphine sulfate extended-release from Egalet Corp. (NASDAQ:EGLT) to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment …

    Published on 1/9/2017
  • COMPANY NEWS: Ipsen acquiring Merrimack's marketed products

    Ipsen Group (Euronext:IPN; Pink:IPSE) is acquiring the commercial business of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) for $575 million up front and up to $450 million in milestones. The deal includes U.S. rights to…

    Published on 1/9/2017
  • COMPANY NEWS: J&J launches JLABS @ NYC

    The Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson (NYSE:JNJ) said it launched JLABS @ NYC, a JLABS incubator in New York City. The facility, slated to open in 2018, was launched in collaboration with …

    Published on 1/9/2017
  • COMPANY NEWS: Novartis' Jimenez gives biosimilar update

    At the JPMorgan Healthcare Conference on Monday, Novartis AG (NYSE:NVS; SIX:NOVN) CEO Joe Jimenez outlined the pharma's commercial strategy for new and upcoming biosimilars, and discussed the company's expectations of …

    Published on 1/9/2017
  • COMPANY NEWS: FDA cancels meeting to discuss Neurocrine's Ingrezza

    FDA cancelled a planned meeting of its Psychopharmacologic Drugs Advisory Committee to discuss an NDA for Ingrezza valbenazine from Neurocrine Biosciences Inc. (NASDAQ:NBIX) to treat tardive dyskinesia. The meeting was …

    Published on 1/6/2017
  • COMPANY NEWS: FDA reviewing Adamas' PD candidate

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) said FDA accepted for review its NDA for ADS-5102 to treat levodopa-induced dyskinesia in Parkinson's disease patients. Its PDUFA date is Aug. 24.The oral extended-release …

    Published on 1/6/2017
  • COMPANY NEWS: iCarbonX names Digital Health Alliance members

    iCarbonX Inc. (Shenzhen, China) said seven companies joined its Digital Life Alliance, through which it aims to combine genetic, biologic and patient-generated data with sequencing and artificial intelligence technology…

    Published on 1/6/2017
  • COMPANY NEWS: Management tracks

    Genomic profiling company Foundation Medicine Inc. (NASDAQ:FMI) said Troy Cox will replace Michael Pellini as CEO, effective Feb. 6. Pellini will remain chairman. Cox was SVP in bio-oncology sales and marketing at the …

    Published on 1/6/2017
  • COMPANY NEWS: Momenta, CSL in deal for Fc multimer proteins

    Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) gained $0.90 to $16.40 on Friday after it announced a license and option deal with CSL Ltd. (ASX:CSL) to develop Fc multimer proteins.CSL will receive exclusive, worldwide …

    Published on 1/6/2017
  • COMPANY NEWS: Regeneron off after judge bars U.S. Praluent sales

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slipped $22.24 to $358.68 on Friday as investors digested Thursday's news that a federal judge granted a permanent injunction barring U.S. sales of hypercholesterolemia …

    Published on 1/6/2017
  • COMPANY NEWS: Alexion rises after 10-Q clarifies accounting

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $12.07 to $139.19 on Thursday after it filed a delayed 10-Q for 3Q16 and revealed that it would not need to restate previously issued financial results. The Audit and …

    Published on 1/5/2017
  • COMPANY NEWS: Ambrx, MabSpace in ADC deal

    Ambrx Inc. (La Jolla, Calif.) and MabSpace Biosciences Co. Ltd. (Suzhou, China) said they plan to discover and develop antibody-drug conjugates for oncology. The partners will use MabSpace's humanized antibody …

    Published on 1/5/2017

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993